{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.9","upperLimit":"14.7","value":"13.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause. If a patient is not known to have died, survival time will be censored at the date of the last contact","dispersionType":"95% Confidence Interval","groups":[{"description":"Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.","id":"OG000","title":"TKI258"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) included all patients who received at least one dose of study drug.\n\nFAS was used for the analysis of efficacy endpoints.","reportingStatus":"POSTED","timeFrame":"36 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}